English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Kanghong Pharma Receives CFDA Approval for China’s First Innovative MAb

Dec. 20, 2013

Chengdu Kanghong Pharmaceutical Group announced that it was granted CFDA approval for its Compaq Sipp ophthalmic injection (Conbercept), a novel treatment for age-related wet macular degeneration. The drug is the first innovative, monoclonal antibody developed in China to gain regulatory approval, a significant milestone. The company believes its drug offers significant advantages over existing western MAbs such as Roche/Genentech’s similar drug, which is marketed as Avastin and Lucentis, giving Conbercept the potential to become a blockbuster.